192 related articles for article (PubMed ID: 18852492)
1. Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk.
Kabbinavar F; Irl C; Zurlo A; Hurwitz H
Oncology; 2008; 75(3-4):215-23. PubMed ID: 18852492
[TBL] [Abstract][Full Text] [Related]
2. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
Kabbinavar FF; Schulz J; McCleod M; Patel T; Hamm JT; Hecht JR; Mass R; Perrou B; Nelson B; Novotny WF
J Clin Oncol; 2005 Jun; 23(16):3697-705. PubMed ID: 15738537
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
Hurwitz HI; Fehrenbacher L; Hainsworth JD; Heim W; Berlin J; Holmgren E; Hambleton J; Novotny WF; Kabbinavar F
J Clin Oncol; 2005 May; 23(15):3502-8. PubMed ID: 15908660
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
Kabbinavar FF; Wallace JF; Holmgren E; Yi J; Cella D; Yost KJ; Hurwitz HI
Oncologist; 2008 Sep; 13(9):1021-9. PubMed ID: 18776057
[TBL] [Abstract][Full Text] [Related]
6. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
Sobrero A; Ackland S; Clarke S; Perez-Carrión R; Chiara S; Gapski J; Mainwaring P; Langer B; Young S;
Oncology; 2009; 77(2):113-9. PubMed ID: 19628950
[TBL] [Abstract][Full Text] [Related]
7. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
Kabbinavar FF; Hambleton J; Mass RD; Hurwitz HI; Bergsland E; Sarkar S
J Clin Oncol; 2005 Jun; 23(16):3706-12. PubMed ID: 15867200
[TBL] [Abstract][Full Text] [Related]
8. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
Grothey A; Hedrick EE; Mass RD; Sarkar S; Suzuki S; Ramanathan RK; Hurwitz HI; Goldberg RM; Sargent DJ
J Clin Oncol; 2008 Jan; 26(2):183-9. PubMed ID: 18182660
[TBL] [Abstract][Full Text] [Related]
9. The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.
Popov I; Milicević M; Radosević-Jelić Lj
Acta Chir Iugosl; 2008; 55(4):11-6. PubMed ID: 19245134
[TBL] [Abstract][Full Text] [Related]
10. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
Kabbinavar F; Hurwitz HI; Fehrenbacher L; Meropol NJ; Novotny WF; Lieberman G; Griffing S; Bergsland E
J Clin Oncol; 2003 Jan; 21(1):60-5. PubMed ID: 12506171
[TBL] [Abstract][Full Text] [Related]
11. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
Kabbinavar FF; Hurwitz HI; Yi J; Sarkar S; Rosen O
J Clin Oncol; 2009 Jan; 27(2):199-205. PubMed ID: 19064978
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Hurwitz H; Fehrenbacher L; Novotny W; Cartwright T; Hainsworth J; Heim W; Berlin J; Baron A; Griffing S; Holmgren E; Ferrara N; Fyfe G; Rogers B; Ross R; Kabbinavar F
N Engl J Med; 2004 Jun; 350(23):2335-42. PubMed ID: 15175435
[TBL] [Abstract][Full Text] [Related]
13. The role of bevacizumab as first-line therapy for colon cancer.
Marshall J
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S43-7. PubMed ID: 16399431
[TBL] [Abstract][Full Text] [Related]
14. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
Hurwitz HI; Yi J; Ince W; Novotny WF; Rosen O
Oncologist; 2009 Jan; 14(1):22-8. PubMed ID: 19144677
[TBL] [Abstract][Full Text] [Related]
15. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
[TBL] [Abstract][Full Text] [Related]
16. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
[TBL] [Abstract][Full Text] [Related]
17. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.
Hurwitz H
Clin Colorectal Cancer; 2004 Oct; 4 Suppl 2():S62-8. PubMed ID: 15479481
[TBL] [Abstract][Full Text] [Related]
18. Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?
Kabbinavar FF; Ellis LM
Clin Colorectal Cancer; 2004 Oct; 4 Suppl 2():S69-73. PubMed ID: 15479482
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
Lin L; Xu JM; Wang Y; Ge FJ; Liu LJ; Zhao CH; Li SS; Liu JZ; Li ZQ
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):786-90. PubMed ID: 21163073
[TBL] [Abstract][Full Text] [Related]
20. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
Budai B; Nagy T; Láng I; Hitre E
Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]